Psychiatry

Back to articles

Varenicline: Mounting evidence supports lack of neuropsychiatric effects

KEY POINT

 

The use of varenicline (Chantix—Pfizer) for smoking cessation did not increase the risk of neuropsychiatric events including depression, suicidal ideation, and aggression, according to a recent large analysis. The rate of neuropsychiatric events in patients taking varenicline was lower than in patients using nicotine replacement therapy. 

SOURCES

 

Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry. 2013;170:1460–1467. http://ajp.psychiatryonline.org/article.aspx?articleid=1738032

Evins AE. Reassessing the safety of varenicline [editorial]. 2013;170:1385–1387. http://ajp.psychiatryonline.org/article.aspx?articleID=1787310